Form 4: ResMed Inc. Executive Sells Shares Under 10b5-1 Plan

ResMed's Global General Counsel, Michael J. Rider, sold 75 shares of common stock at $230.99 per share on January 2, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Michael J. Rider, Global General Counsel of ResMed Inc., sold 75 shares of ResMed common stock on January 2, 2025.
• The sale was executed at a price of $230.99 per share.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 11, 2024.
• Following the transaction, Mr. Rider directly owns 9,038 shares of ResMed common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive's stock sale under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine filing related to insider trading activity and is common for executives of publicly traded companies. The use of a 10b5-1 plan indicates a pre-planned sale, which is a common practice to avoid accusations of trading on inside information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice among executives at publicly traded companies like ResMed to manage their stock sales.
• Similar filings are regularly seen from executives at comparable companies such as Philips and Medtronic, indicating a common approach to stock transactions.
• The volume of shares sold is relatively small compared to the total outstanding shares of ResMed, suggesting this is a routine transaction rather than a significant change in executive holdings.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

ResMed, insider trading, Form 4, stock sale, Rule 10b5-1, executive, Michael J. Rider, RMD